THE Therapeutic Goods Administration has published its summary of price disclosure price reductions for the 2018 April Cycle, which is the Fourth Remove Originator cycle, on the Price Disclosure (SPD) web page.
The posting includes details around flow-on reductions for F2 combination items.
Indicative prices for 01 Apr 2018, including price to pharmacy, dispensed price for maximum quantity and price premiums, will be published later this month, while final prices will be available from early Mar 2018.
The largest percentage reduction is a 44.22% price cut since Oct 2017 on the PBS price of Lamivudine oral solution, while reductions of more than 30% apply to cefepime, pemetrexed, esomeprazole and irinotecan.
There's also additional detail on the outcomes if a proposed amendment to legislation is passed by parliament - see pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jan 18
